Zacks Investment Research Upgrades Osmotica Pharmaceuticals (NASDAQ:OSMT) to Hold

Zacks Investment Research upgraded shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) from a sell rating to a hold rating in a research note published on Thursday, Zacks.com reports.

According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “

Other analysts also recently issued reports about the company. Wells Fargo & Co set a $14.00 price objective on Osmotica Pharmaceuticals and gave the company a buy rating in a research note on Thursday, March 28th. Barclays initiated coverage on Osmotica Pharmaceuticals in a research note on Tuesday. They set an overweight rating and a $11.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $14.00.

OSMT traded up $0.10 on Thursday, hitting $3.20. 5,095 shares of the company traded hands, compared to its average volume of 154,404. The company has a quick ratio of 1.41, a current ratio of 1.70 and a debt-to-equity ratio of 0.71. The company has a market cap of $164.86 million and a PE ratio of -6.27. Osmotica Pharmaceuticals has a 12-month low of $2.20 and a 12-month high of $9.90.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.08). The business had revenue of $57.13 million during the quarter, compared to analysts’ expectations of $53.58 million. As a group, sell-side analysts expect that Osmotica Pharmaceuticals will post -0.25 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Northern Trust Corp purchased a new position in shares of Osmotica Pharmaceuticals during the 4th quarter valued at $615,000. BlackRock Inc. purchased a new position in shares of Osmotica Pharmaceuticals during the 4th quarter valued at $3,682,000. Broadfin Capital LLC purchased a new position in shares of Osmotica Pharmaceuticals during the 4th quarter valued at $4,096,000. Millennium Management LLC purchased a new position in shares of Osmotica Pharmaceuticals during the 4th quarter valued at $2,568,000. Finally, Great Point Partners LLC purchased a new position in shares of Osmotica Pharmaceuticals during the 4th quarter valued at $11,625,000. 11.64% of the stock is owned by institutional investors and hedge funds.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Featured Article: Dollar Cost Averaging

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.